Inhaled nebulised unfractionated heparin (UFH) for the treatment of hospitalised patients with COVID-19: A randomised controlled pilot study

This publication has 16 references indexed in Scilit:

• Unfractionated heparin inhibits live wild type SARS‐CoV‐2 cell infectivity at therapeutically relevant concentrations
  British Journal of Pharmacology, 2020
• SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2
  Cell, 2020
• Clinical Versus Statistical Significance in Studies of Thoracic Malignancies
  Journal of Thoracic Oncology, 2020
• Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
  Critical Care, 2020
• Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis
  Critical Care and Resuscitation, 2020
• Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study
  Pulmonary Pharmacology & Therapeutics, 2018
• A Trial of Nebulised Heparin to Limit Lung Injury following Cardiac Surgery
  Anaesthesia and Intensive Care, 2016
• Pharmacology of Heparin and Related Drugs
  Pharmacological Reviews, 2016
• Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial
  Critical Care, 2010
• Nebulized heparin reduces levels of pulmonary coagulation activation in acute lung injury
  Critical Care, 2010